Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.

Mimi I Hu Steven G Waguespack Chrysoula Dosiou Paul W Ladenson Masha J Livhits Lori J Wirth Peter M Sadow Jeffrey F KraneBrendan C StackMark E ZafereoSyed Z AliSteven P WeitzmanYangyang HaoJoshua E BabiarzGiulia C KennedyRichard T Kloos

Published in: The Journal of clinical endocrinology and metabolism (2021)

This large study demonstrates that almost one-half of Bethesda III/IV Afirma GSC suspicious and most Bethesda V/VI nodules had at least 1 genomic variant or fusion identified, which may optimize personalized treatment decisions.

Keyphrases

fine needle aspiration
ultrasound guided
single cell
copy number
gene expression
combination therapy
neural network